Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Burroughs Wellcome licenses Navelbine

Executive Summary

The semi-synthetic vinca alkaloid vinorelbine from the French firm Pierre Fabre Medicament will be marketed in the U.S. and Canada by B-W under the agreement. The anticancer drug "has shown activity in non-small cell lung cancer and breast cancer in Phase II trials in Europe," the firm said. B-W expects to begin clinicals for lung and breast cancer in early 1990. Fabre has obtained in return certain rights to a future anticancer compound from Wellcome in Europe.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts